Well, I do remember CYDY hitting $4 per share few years back so it is possible to have organic growth and up-list. I was investing in ONVO when they traded in the OTC and once the company up listed it went above and beyond my expectations, and they are yet to turn a profit 5 years later. Before we do decide to up-list we better have all of our ducks in a roll and plans of how to start selling the product etc.
In my view if we are looking to up-list to one of the exchanges, then we are planing to raise more capital from diverse players, and manufacture and sell Pro-140 in our terms, and hope once cash-flow is generated and there is patient demand for the drug a partner and buy out would come.
Also to add, a buyout on a major exchange should warrant a larger offer, and be more transparent for BP companies who have to run acquisitions through their boards and please shareholders as well.
News 
Market Data 
Discover 
AI
